Interventions in the Acute Phase of Myocardial Infarction

1. Front Matter

   Pages i-xiii

   PDF

2. Models to Study Experimental Infarction

   1. Experimental Models and Endpoints for Evaluating Interventions in the Acute Phase of Myocardial Infarction —An Anatomic Approach

      • Keith A. Reimer, Robert B. Jennings

      Pages 1-11

   2. Models to Study Experimental Infarction — Pharmacologic

      • Stewart J. Ehrreich

      Pages 12-19

   3. Pharmacokinetics of Anti-Arrhythmic Agents in Acute Myocardial Infarction

      • Raymond L. Woosley, Irene Cerskus, Dan M. Roden

      Pages 20-36

3. Indices to Define Infarct Size

   1. Limitations of Electrophysiologic Techniques in Defining Myocardial Infarct Size

      • E. Neil Moore, Joseph F. Spear

      Pages 37-47

   2. Estimates of Injury After Infarction Evolving Spontaneously or in Response to Coronary Thrombolysis

      • Burton Sobel

      Pages 48-60

   3. Measurement of Myocardial Infarct Size Using Nuclear Cardiology Methods

      • James T. Willerson, Samuel E. Lewis, James R. Corbett, Christopher L. Wolfe, Robert W. Parkey, L. Maximilian Buja

      Pages 61-75

   4. Echocardiographic Approaches to the Evaluation of Acute Myocardial Infarction

      • Andrew J. Kemper, Alfred F. Parisi

      Pages 76-87

   5. Two Dimensional Echocardiography in Acute Myocardial Infarction: Clinical Applications

      • Ioannis P. Panidis, Joel Morganroth

      Pages 88-102

   6. Panel on Indices to Define Infarct Size

      • Joel Morganroth

      Pages 104-112

4. Pharmaceutical Interventions to Reduce Infarct Size

   1. The Case for Prophylactic Lidocaine in Acute Myocardial Infarction

      • Donald C. Harrison

      Pages 113-118

   2. Infarct Size Reduction by Antiarrhythmic Prophylaxis — A Contrary View

      • R. W. F. Campbell, P. Kertes

      Pages 119-128

   3. Pharmaceutical Interventions to Reduce Infarct Size — Streptokinase

      • Peter Rentrop

      Pages 129-137

   4. Streptokinase in Acute Myocardial Infarction

      • Sidney Goldstein, Fareed Khaja

      Pages 138-143

   5. Vasodilators in Acute Myocardial Infarction

      • Jay N. Cohn

      Pages 144-151

   6. Panel on Pharmaceutical Interventions to Reduce Infarct Size

      • Jay Cohn

      Pages 152-167

   7. Early Intravenous Atenolol in Suspected Acute Myocardial Infarction: Final Report of a Randomised Clinical Trial

      • S. Yusuf, D. Ramsdale, P. Sleight, P. Rossi, R. Peto, M. Pearson et al.

      Pages 168-189

   8. Calcium Channel Blockers and Limitation of Myocardial Infarction Size

      • Zoltan G. Turi

      Pages 190-197

   9. Steroid Treatment of Acute Myocardial Infarction: Some Implications for Clinical Trials in General

      • P. L. Dern

      Pages 198-200

   10. Evaluation of Inotropic Therapy

       • Raymond Lipicky

       Pages 201-204

In the 1980's a primary focus for intense cardiovascular research is in the treatment of patients with acute myocardial infarction. Although the prevalence of this syndrome has been decreasing in the United States, still over 1.5 million patients develop myocardial infarction per year. There is about a 20% chance of a North American male developing myocardial in­ farction before the age of 65. The in-hospital mortality still remains at ap­ proximately 10070-15070 and advances in pharmacologic and device therapy have allowed for the intensification of research in the treatment of patients with acute myocardial infarction. The following manuscripts represent the collective efforts of academic in­ vestigators in the United States and abroad as well as members of the phar­ maceutical industry, and the Food and Drug Administration to address the issues involved in interventions in the acute phase of myocardial infarction. State-of-the-art papers addressing important topics are followed by discus­ sion sections which have allowed participants to express their own viewpoints leading to a consensus opinion. The first part of this Symposium addresses the models of experimental myocardial infarction followed by the important issue of how one defines myocardial infarction size. The latter is extremely important to be certain that endpoints of therapeutic or device interventions are objective and reproducible. A detailed description of the pharmacological interventions to reduce myocardial infarction size as well as newer devices to effect mechanical and electrical disorders provide an up-to-date summary of current opinion.

• cardiology
• cardiovascular
• drugs
• echocardiography
• myocardial infarction

Policies and ethics